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puesto que 6sta estimula la actividad de AC mediante la 
inhibici6n de la protefna regulatoria inhibidora por la ribosila- 
ci6n por ADP de la subunidad alpha de la protefna Gi. Se utiliz6 
toxina del c61era (CT) (10 ng/ml) por cuanto 6sta activa en 
forma selectiva las proteinas G estimulantes. La actividad de 
AC fue determinada pot la tasa de conversi6n de [aYP]ATP a 
cAMP en pmol/mg de proteina pot 30 minutos. En 11 pacientes 
los niveles de AC estimulada por PT (8.55 -+ 1.7) en los tejidos 
norma!es fueron superiores a los niveles basales de AC (5.14 -+ 
0.9, p < 0,01). Sin embargo, no se observ6 diferencia entre los 
niveles basales y los niveles estimulados por PT en los tejidos 
neopl~isicos (6.43 -+ 1.0 y 6.87 -+ 1.8, respectivamente). Esto 
sugiere que existe menos proteina Gi en los neoplasmas puesto 
que ! a respuesta de AC a la PT fue mayor en un 170% en los 
tejidos normales y no se present6 estimulaci6n significativ a en 
los tejidos neopl~sicos. En contraste, la respuesta de AC a la 
CT (10 t~g/ml) que directamente activa las protefnas regulatorias 
guanil nuc!eotidas, fue mayor en el tejido neopl~isico tiroideo 
(!74.3 -+ 30.1) q u e e n  el tejido tiroideo normal (78.5 -+ 16.3) 
extraidos del mismo paciente (p < 0.01). 
Estos experimentos demuestran que la mayori a de los neo- 
plasmas tiroideos poseen menos proteina Gi y m~is proteina Ge, 
lo cual probablemente explica el mayor grado de respuesta de la 
AC a la TSH en los neoplasmas tiroideos. El mayor est/mulo de 
Ge y el mayor grad0 de respuesta de la AC en los neoplasmas 
puede representar la raz6n del crecimiento m~is rftpido de los 
tumores benignos y malignos de la tiroides. 
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More information is needed to understand the biologic behavior 
of differentiated thyroid carcinomas. Historically, a good prog- 
nosis has correlated with the patient 's age, under 45 years, and 
smaller tumors without capsular or vascular invasion. A poorer 
prognosis is found in older patients with more extensive dis- 
ease. To date, no single microscopic or ultrastructural feature 
has emerged as a reliable means of predicting a fatal outcome 
[1]. The extent of thyroidectomy as a determinant of outcome 
continues to be debated among experienced thyroid surgeons. 
Clearly, there is a need for more basic knowledge on the 
mechanisms of growth in both benign and malignant thyroid 
neoplasms. Clark and co-workers continue to pursue this sub- 
ject and their current report on regulatory proteins in thyroid 
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tissue is another fine example of their efforts. They found that 
thyroid neoplasms have less inhibiting guanyl nucleotide regu- 
latory protein (Gi) and more stimulating guanyl nucleotide 
regulatory protein (Gs) when compared to normal thyroid 
tissue. The authors conclude that this altered ratio of regulatory 
proteins accounts for the greater adenylate cyclase response to 
thyroid stimulating hormone in thyroid neoplasms and may 
account for the more rapid growth of both benign and malignant 
thyroid neoplasms. While their methodology appears to be 
sound, the authors give no details in their report  on the exact 
nature of the neoplastic thyroid tissue they studied nor any data 
on the difference between malignant and benign neoplastic 
tissue. The lack of specific data is a major weakness of this 
report. One would have to conclude that Clark and co-workers 
found no difference between benign and malignant neoplasms, 
which is, of course, disappointing. The authors should direct 
future efforts at detecting differences between thyroid neo- 
plasms. Nonetheless,  this report  is significant in its relevance to 
the management of thyroid cancer since it sheds light on the 
possible mechanisms of tumor growth and TSH suppression by 
thyroid feeding. 
The prognostic value of nuclear DNA content in patients with 
thyroid carcinomas is another area of intense study [24] .  The 
presence of an increased DNA content when compared to a 
diploid cell is the basic definition of aneuploidy and is a well 
recognized feature of human cancer. A comparison of the ratio 
of regulatory proteins with nuclear DNA content appears to be 
a worthwhile area for future research. Such efforts would be 
facilitated by the development of monoclonal antibodies to both 
Gi and Gs proteins if flow cytometric DNA analysis is to be 
used. 
If a consistent approach to the treatment of thyroid carcino- 
mas is to emerge, then a clear understanding of the mechanisms 
of tumor growth is essential. More basic research, like that 
reported by Clark and colleagues, is the keystone of that effort. 
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